お知らせ • Jun 18
Natera Showcases Prospera Test Utility with 21 Presentations At American Transplant Congress
Natera, Inc. announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant. Even when biopsy results are negative for rejection, elevated Prospera dd-cfDNA levels were strongly predictive of future adverse outcomes, including eGFR decline, DSA positivity, and graft loss. New data from the PEDAL study in 346 kidney transplant patients with non-rejection biopsy results showed that patients with positive Prospera results, which occurred in 18.2% of these cases, had significantly higher rates of adverse outcomes, including >6X the rate of graft loss. The data suggest that positive dd-cfDNA results indicate an increased risk for adverse outcomes, even when biopsy does not show rejection. Patients with persistently low Prospera dd-cfDNA levels had reliable and significantly lower adverse outcome rates, which may enable confident decisions to lower immunosuppression. In a new analysis of 989 kidney transplant recipients from the ProActive study, when a patient’s Prospera dd-cfDNA donor-fraction remained <0.5%, patients had significantly lower rates of adverse outcomes, including ~12X reduced odds of future rejection and ~5.5X reduced odds of future graft loss. These results demonstrate that low Prospera dd-cfDNA was prognostic of durable graft stability and reiterate the importance of ongoing and regular monitoring. Full list of Natera presentations at ATC: June 20, 5:45 PM ET | Abstract #A003 Presenter: Catherine Spellicy, Ph.D. The Edge of Detection: Defining Critical Thresholds for the Prospera Donor-Derived Cell-Free DNA Transplant Rejection Screen. June 20, 5:45 PM ET | Abstract #A363 (ProActive) Presenter: Jonathan Bromberg, M.D., Ph.D. Consistently Low Donor-Derived Cell-Free DNA Identifies Allograft Stability in Kidney Transplant Recipients. June 20, 5:45 PM ET | Abstract #A380 Presenter: Mita Banik, Ph.D. A Novel Hierarchical Machine Learning Framework for Predicting Kidney Transplant Rejection Subtype. June 21, 8:30 AM ET | Abstract #254 Presenter: Ginger DeLario, Ph.D., M.T. (ASCP), CPTC Are Transplant APPs Ready for Certification? National Findings from the American Board for Transplant Certification (ABTC). June 21, 2:45 PM ET | Abstract #B258 Presenter: Quinn Stein, M.S., CGC Busting the Age Myth: Clinically Significant Genetic Findings in Living Donor Candidates Are Not Limited to the Young. June 21, 2:45 PM ET | Abstract #B261 Presenter: Keysha M. López Vega, M.D. Genetic Testing in Kidney Transplant Candidates and Recipients: Three Cases of Adenine Phosphoribosyltransferase (APRT) Deficiency Identified in Puerto Rico. June 21, 2:45 PM ET | Abstract #B266 Presenter: Maggie Westemeyer, M.S., CGC Positive Genetic Test Results in Living Kidney Donor Candidates: Common and Broadly Distributed Across Genes. June 21, 5:00 PM ET | Abstract #490 (Oral Presentation) Presenter: Quinn Stein, M.S., CGC Carrier Findings Are Common and Clinically Relevant in Living Kidney Donor Candidates. June 22, 8:15 AM ET | Abstract #554 (Trifecta Heart, Oral Presentation) Presenter: Katelynn Madill-Thomsen, Ph.D. In heart transplants, DSA-negative and DSA-positive antibody-mediated rejection have similar molecular features, timing, dd-cfDNA and leukocyte composition. June 22, 2:45 PM ET | Abstract #C090 Presenter: Gregory Lewis, M.D. Biopsy to Biomarker: Evolution of Post-Heart Transplant Surveillance Practices from the ProTECT Study. June 22, 2:45 PM ET | Abstract #C093 (Trifecta Heart) Presenter: Martina Mackova, Ph.D. Comparing Histological Acute Cellular Rejection Grade 1R with Molecular Microscope Diagnostic System Classifiers and Donor-Derived Cell-Free DNA (dd-cfDNA) Levels. June 22, 2:45 PM ET | Abstract #C100 (Trifecta Heart) Presenter: Patrick Gauthier, Ph.D. Incremental Increase in Donor-Derived Cell-Free DNA (dd-cfDNA) and Risk of Molecular Rejection in Heart Transplant (HT) Recipients. June 22, 2:45 PM ET | Abstract #C157 Presenter: Meg Hager, M.S., MPH, CGC Conversations That Lead to Action: Genetic Counselors and Living Kidney Donors. June 22, 2:45 PM ET | Abstract #C358 Presenter: Shelley Hall, M.D. Donor-Derived Cell-Free DNA (dd-cfDNA) and Clinical Outcomes in Heart Transplant (HT) Patients (Pts) with Antibody Mediated Rejection (AMR): ProTECT Study. June 23, 2:30 PM ET | Abstract #D083 (ProActive) Presenter: Matthew Cooper, M.D. Association Between dd-cfDNA and Future Development of DSA or Rejection in Kidney Transplant Recipients with TCMR. June 23, 2:30 PM ET | Abstract #D120 (ProActive) Presenter: Sanjeev Akkina, M.D. Dd-cfDNA in Kidney Transplant Recipients (KTRs) with Cancer. June 23, 2:30 PM ET | Abstract #D266 Presenter: Justin Rosenheck, D.O. Torque Teno Virus (TTV) Viral Load (VL) Correlates with Tacrolimus (TAC) Levels but Not Lymphocyte Subsets or Immunoglobulins After Lung Transplantation (LT). June 23, 2:30 PM ET | Abstract # D285 Presenter: Abraham Matar, M.D. Donor-Derived Cell-Free DNA for Detection of Rejection After Pancreas Transplantation. June 24, 9:30 AM ET | Abstract #1314 (Trifecta Heart, Oral Presentation) Presenter: Martina Mackova, Ph.D. In Heart Transplants Current Standard-of-Care Management of TCMR and ABMR is Often Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA. June 24, 9:30 AM ET | Abstract #1316 (Trifecta Kidney, Oral Presentation) Presenter: Philip Halloran, M.D. Current Standard-of-Care Management of TCMR and ABMR in Kidney Transplant Patients is Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA. June 24, 9:30 AM ET | Abstract #1331 (Oral Presentation) Presenter: Gaurav Gupta, M.D. Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR). June 24, 9:30 AM ET | Abstract #1333 (PEDAL, Oral Presentation) Presenter: Yasir Qazi, M.D., Ph.D., FACS Post-Rejection Donor-Derived Cell-Free DNA and Serum Creatinine Trends in Kidney Transplant Recipients. June 24, 9:30 AM ET | Abstract #1335 (PEDAL, Oral Presentation) Presenter: Suphamai Bunnapradist, M.D. Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Biopsy-Negative Kidney-Transplant Recipients.